Donate

Washington Wire: September 2019

September 30, 2019

The drug pricing debate聽in Washington resumed when Congress returned from its summer recess 鈥 though many observers question whether Congress will be able to pass legislation this year, due to policy disagreements between the majority and minority parties; the short period of time available before the 2020 elections; and the spillover effects of the impeachment […]

Washington Wire: July 2019

July 31, 2019

FEATURED STORIES Product recall announced; patient organizations are in ongoing communications with manufacturer Bayer announced the recall of two lots of Kogenate庐聽FS antihemophilic factor (recombinant) 2000 I.U. vials on July 19, 2019. Bayer announced that 3000 I.U. of one product (Jivi), past its expiration date, had been mislabeled as another product (2000 I.U. of Kogenate […]

Word From Washington: CMS Drops Proposal to Allow Medicare Plans to Limit Coverage of “Protected Class” Drugs

May 17, 2019

  The U.S. Centers for Medicare and Medicaid Services (CMS) released a final rule yesterday on drug pricing in the Medicare Advantage and Medicare Part D programs. In its final rule, CMS chose not聽to implement a harmful change that it had initially put forward 鈥 a change strongly opposed by HFA and numerous other patient […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.